Author

S. Schoffelen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1 Assay:protein sequence· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Arnsdorf· 2 shared N. E. Lewis· 2 shared A. G. Peralta· 1 shared A. H. Hansen· 1 shared A. W. T. Chiang· 1 shared B. Choudhury· 1 shared B. G. R. Voldborg· 1 shared B. G. Voldborg· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

J. Arnsdorf

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

LeGenD: determining N-glycoprofiles using an explainable AI-leveraged model with lectin profiling

H. Li, A. G. Peralta, S. Schoffelen, A. H. Hansen, J. Arnsdorf, S.-M. Schinn, J. Skidmore, B. Choudhury, M. Paulchakrabarti, B. G. Voldborg, A. W. T. Chiang, N. E. Lewis

LeGenD predicts N-glycan structures and their abundance using lectin-binding patterns and AI, trained on glycoprofiles from recombinant proteins.

bioRxiv · Mar 27, 2024 · PreprintBioengineering

Glycoengineered recombinant alpha1-antitrypsin results in comparable in vitro and in vivo activities to human plasma-derived protein

F. Rocamora, S. Schoffelen, J. Arnsdorf, E. A. Toth, Y. Abdul, T. E. Cleveland, S. P. Bjorn, M. Y. M. Wu, N. G. McElvaney, B. G. R. Voldborg, T. R. Fuerst, N. E. Lewis

This study generates glycoengineered recombinant alpha1-antitrypsin with in vitro and in vivo activities comparable to plasma-derived A1AT, offering a sustainable therapeutic alternative.

bioRxiv · Mar 27, 2024 · PreprintBioengineering